توریہ کی حقیقت، ضرورت اور اس کا حکم: ایک تحقیقی جائزہ

Islam is a religion of peace, love and prosperity. It emphasis on moral values and strongly forbids from immoral acts. Commitment to the former is ultimate way to the paradise, while the latter leads to Hell, which is an abode, where deviants from the righteousness are punished for their misdeeds. The Holy Prophet Muhammad (ﷺ) showed the importance of morality through the deeds and actions. “Ta┴riyā” is an act which is a part of morality. It is an act which escapes a human being from telling a lies strongly forbidden in Islam, being a root cause of manly social avoid. Usually“Ta┴riyā” is adopted so as to avoid differences and turmoil on a group of individuals. By“Ta┴riyā” means speaking a statement which is equivoques i.e. At the same it gives too meaning apparent and the hidden. Now the question arises whether “Ta┴riyā” is considered as lie or truth. It cannot be termed either lie or truth. However, in many traditions, it has been negated as a lie. At some occasions, when a person feels to tell a lie, for the sake of bringing peace, then it is advised than he should bring on use the act of “Ta┴riyā” but. The reality manipulated be in such a way so it could be termed as lie.

Studies on the Use of Hbv Epitope Chimeras

Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Major advances have been made in the treatment of Hepatitis B recent years. However, much remains to be accomplished because current antiviral drugs do not eradicate infection. The currently licensed hepatitis B vaccines, consisting of recombinant hepatitis B surface antigen (HBsAg) and alum, are highly effective and induce protective antibody titers in 95% of vaccinated individuals after 3 immunizations before onset of HBV infection. Present studies were aimed to develop chimeric vaccine (proteins) that may stimulate B- and T- cell responses and generate enhance immune response to treat the HBV patients after infection. In this regard, five HBV chimeric vaccine constructs were designed and developed using the HBcAg gene encoding amino acids 1-78 and amino acids 80-144. Amino acid- position 79 where deleted and replaced with preS epitopes sequences. All five chimeric constructs (pIJMcsc-1, pIJMcsc-2, pIJMcsc-3. pIJMcsc-4 and pIJMcsc-5) contained HBcAg as a carrier molecule for the epitopes of preS regions primed HBcAg- specific antibodies response. These constructs (chimeric plasmids) were transformed into E.coli to see the protein product on SDS-PAGE. The expressed proteins (csc-1, csc-2, csc-3. csc-4 and csc-5) were purified based on affinity chromatography using His tag at the C terminal of expressed proteins. The purified chimeric proteins were further subjected to Enzyme linked Immunosorbent assay (ELISA) and western blotting assays using secondary anti- rabbit AP conjugated antibody and secondary anti-mouse AP-conjugated antibody respectively. All five chimeric proteins showed positive antibody response. In vivo study was performed for chimeric protein (csc-5) only. This chimeric protein (csc-5) was evaluated in C57BL/6J mice for activation of humoral and cellular immune responses, primed both HBcAg- specific T cells and antibodies to preS1. IXResult obtained indicated that the csc-5 protein can induce HBV-specific antibodies and T cells, two functions that well complement the activity of antiviral compounds. Thus, the csc-5 protein may be a future component in therapy for chronic HBV infections where the host is gaining a sustained control of the HBV infection and also a viable approach to develop an effective bi-functional therapeutic vaccine as an add-on for treatment of chronic HBV.